Recent epidemiological trends in HCV-infection in Ukraine
Abstract
Today liver damage caused by Hepatitis C Virus (HCV) is widespread and included in the list of diseases of a social character. The aim of this research is to identify the peculiarities and summarize the epidemiological characteristics of HCV-infection in Ukraine, based on a retrospective analysis of detecting HCV based on antibodies, RNA and its genotyping, taking into account the sex and age of infected people in regions of Ukraine and particularly in Dniprо and Dnipropetrovs’k region. The research materials were provided by sampling the results of screening tests and qualitative detection of RNA-HCV genotyping (1a, 1b, 2 and 3). The survey involved 10,394 people from different regions of Ukraine (2014–2016). HCV-infection was detected in 3,436 of them, accounting on average for 32.5% of those surveyed. We analysed further 1,113 cases with positive RNA-HCV genotyping. Detection of infection by age periods was: 0–9 years old – 0.8%, 10–19 – 0.5%, 20–29 – 11%, 30–39 – 32%, 40–49 – 30%, 50–59 – 19.5%, 60–69 – 5.0% and 70–79 – 1.0%. 603 (54.2%) infected people belonged to genotype 1; 107 (9.6%) belonged to genotype 2; 403 (36.2%) belonged to genotype 3. Women were more frequently infected by genotype 1b, with increased percentage of 1ab; men often had genotype 3. 1,513 inhabitants of Dniprо and Dnipropetrovs’k region were sent to be tested for anti-HCV in 2011–2015. The percentage of positive anti-HCV showed a sharp increase from 28% to 64% over the observation period. Detection of HCV by age periods was: 0–9 years old – 0.9%, 10–19 – 1.5%, 20–29 – 9.5%, 30–39 – 27.6%, 40–49 – 27.8%, 50–59 – 23.2%, 60–69 – 8.8% and 70–79 – 0.7%. 1 genotype was identified in 262 (56.8%) infected patients among 461 HCV-infected, 38 (8.2%) had genotype 2, 61 (35%) had genotype 3. 2.6% were diagnosed 1ab. In both populations that were tested, the frequency of detection of HCV was similar among men and women. Gender differences in the spread of genotype 2 haven’t been identified. The disease HCV remains one of the urgent problems of public health in Ukraine.References
Caccamo, G., Saffioti, F., & Raimondo, G. (2014). Hepatitis B virus and hepatitis C virus dualinfection. World Journal of Gastroenterology, 20(40), 14559–14567.
Cacoub, P., & Comarmond, C. (2017). New insights into HCV-related rheumatologic disorders: A review. Journal Advanced Research, 2, 89–97.
Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244(4902), 359–362.
Derzhstandart Ukrai’ny. Medychni laboratorii’. Vymogy dlja jakosti ta kompetentnosti [National standard of Ukraine. Medical laboratories. Requirements for quality and competence] (EN ISO 15189:2012, IDT) DSTU EN ISO 15189: 2015, DP UkrNDNC, Kyiv (in Ukrainian).
El-Shabrawi, M. H., & Kamal, N. M. (2013). Burden of pediatric hepatitis C. World Journal of Gastroenterology, 19(44), 7880–7888.
Fiorino, S., Bacchi-Reggiani, L., de Biase, D., Fornelli, A., Masetti, M., Tura, A., Grizzi, F., Zanello, M., Mastrangelo, L., Lombardi, R., Acquaviva, G., di Tommaso, L., Bondi, A., Visani, M., Sabbatani, S., Pontoriero, L., Fabbri, C., Cuppini, A., Pession, A., & Jovine, E. (2015). Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review. World Journal of Gastroenterology, 21(45), 12896–12953.
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014). Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal Hepatology, 61, S45–57.
Guaraldi, G., Lonardo, A., Maia, L., & Palella Jr., F. J. (2017). Metabolic concerns in aging HIV-infected persons: From serum lipid phenotype to fatty liver. AIDS, 31, S147–S156.
Larsen, C., Bousquet, V., Delarocque-Astagneau, E., Pioche, C., Roudot-Thoraval, F., & Desenclos, J. C. (2010). Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. Journal of Medical Virology, 82(10), 1647–1654.
Lee, M. H., Yang, H. I., Lu, S. N., Jen, C. L., You, S. L., Wang, L. Y., L’Italien, G., Chen, C. J., & Yuan, Y. (2014). Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. International Journal of Cancer, 135(5), 1119–1126.
Lee, M. H., Yang, H. I., Yuan, Y., L’Italien, G., & Chen, C. J. (2014). Epidemiology and natural history of hepatitis C virus infection. World Journal of Gastroenterology, 20(28), 9270–9280.
Lingala, S., & Ghany, M. G. (2015). Natural history of hepatitis C. Gastroenterology Clinics of North America, 44(4), 717–734.
Lonardo, A., Adinolfi, L. E., Restivo, L., Ballestri, S., Romagnoli, D., Baldelli, E., Nascimbeni, F., & Loria, P. (2014) Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World Journal of Gastroenterology, 20(23), 7089–7103.
Magiorkinis, G., Magiorkinis, E., Paraskevis, D., Ho, S. Y. W., Shapiro, B., Pybus, O. G., Allain, J.-P., & Hatzaki, A. (2009). The global spread of hepatitis C virus 1a and 1b: A phylodynamic and phylogeographic analysis. PLOS Medicine, 6(12), e1000198.
Matsumura, H., Nirei, K., Nakamura, H., Higuchi, T., Arakawa, Y., Ogawa, M., Tanaka, N., & Moriyama, M. (2013). Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors. World Journal of Gastroenterology, 19(30), 4887–4896.
Miller, F. D., Elzalabany, M. S., Hassani, S., & Cuadros, D. F. (2015). Epidemiology of hepatitis C virus exposure in Egypt: Opportunities for prevention and evaluation. World Journal of Gastroenterology, 7(28), 2849–2858.
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013). Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology, 57(4), 1333–1342.
Mühlberger, N., Schwarzer, R., Lettmeier, B., Sroczynski, G., Zeuzem, S., & Siebert, U. (2009). HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality. Bio Med Central Public Health, 9, 34.
Negro, F., & Esmat, G. (2017). Extrahepatic manifestations in hepatitis C virus infection. Journal Advanced Research, 2, 85–87.
Shcherbinina, M. B., & Shevchenko, T. N. (2016). Vnepechenochnye projavlenija hronicheskogo virusnogo gepatita С: svoevremennaja diagnostika uluchshaet prognoz [Extrahepatic manifestations of chronic hepatitis C: early diagnosis improves prognosis]. Ukraїns’kij Terapevtichnij Zhurnal, 3, 93–99 (in Russian).
Smith, D. J., Combellick, J., Jordan, A. E., & Hagan, H. (2015). Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. International Journal of Drug Policy, 10, 911–921.
Soipe, A. I., Razavi, H., Razavi, D., Galárraga, O., Taylor, L. E., & Marshall, B. D. L. (2016). Chronic hepatitis C virus (HCV) burden in Rhode Island: Modelling treatment scale-up and elimination. Epidemiology and Infection, 144(16), 3376–3386.
Sokal, E., & Nannini, P. (2017). Hepatitis C virus in children: The global picture. Archives of Disease in Childhood.
Tovo, P. A., Calitri, C., Scolfaro, C., Gabiano, C., & Garazzino, S. (2016). Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. World Journal of Gastroenterology, 22(4), 1382–1392.
Wedemeyer, H., Dore, G. J., & Ward, J. W. (2015). Estimates on HCV disease burden worldwide ‒ filling the gaps. Journal of Viral Hepatitis, Suppl. 1, 1–5.
WHO (2016). Guidelines for the screening, care and treatment of persons with chronic hepatitis С infection. Updated version.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
